Selected article for: "cardiovascular disease and fatality rate"

Author: Kang, Yu; Chen, Tiffany; Mui, David; Ferrari, Victor; Jagasia, Dinesh; Scherrer-Crosbie, Marielle; Chen, Yucheng; Han, Yuchi
Title: Cardiovascular manifestations and treatment considerations in covid-19
  • Cord-id: 5l513o55
  • Document date: 2020_4_30
  • ID: 5l513o55
    Snippet: Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiov
    Document: Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of covid-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.

    Search related documents:
    Co phrase search for related documents
    • absent mild and lung injury: 1
    • absent mild and magnetic resonance: 1
    • accelerated ageing and acute respiratory syndrome: 1, 2, 3
    • accelerated ageing and low mortality: 1, 2, 3
    • accumulate evidence and acute respiratory syndrome: 1
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and acute coronary syndrome: 1
    • ace inhibitor and acute heart failure: 1
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • ace inhibitor and low heparin: 1
    • ace inhibitor and low molecular weight heparin: 1